iOnctura Extends Series A to EUR 20.1 million. 3B Future Health Fund Joins Blue Chip Investor Syndicate. Accelerate Development of Next Generation Molecules Targeting Cancer and Fibrosis.

Logo iOnctura

Geneva, Switzerland, 14 July 2020: iOnctura SA, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, today announces that it has raised an additional EUR 5.1 million bringing the total Series A financing to EUR 20.1 million. New investor 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR joins the existing blue chip investor syndicate of M Ventures, INKEF Capital, VI Partners, and Schroder Adveq, which all participated in the extension.

(more…)

Read More

Inositec’s INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications

Zurich, Switzerland, February 5, 2020 – Inositec, a pioneer in the development of life-saving small molecule drugs based on myo-inositol hexaphosphate (IP6), announced today that positive proof-of-concept data on INS-3001, a novel cardiovascular calcification inhibitor, were published in Nature Communications (DOI: 10.1038/s41467-019-14091-4). INS-3001 was found to be a potent and well tolerated inhibitor of pathological soft tissue calcification in preclinical studies. Calcification, particularly in arterial walls and cardiac valves, leads to an increase in cardiac events. Inositec is developing INS-3001 for a number of cardiovascular indications caused by calcification, including aortic valve stenosis.

(more…)

Read More

JenaValve Technology Closes $50 Million Financing

Irvine, Calif. (February 5, 2020) – JenaValve Technology, Inc., developer and manufacturer of the JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of aortic valve disease, announces that it has raised $50 million in an equity financing led by Bain Capital Life Sciences. Additional participants in the financing included existing investors Andera Partners, Gimv, Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners. The Company also announces the appointment of Andrew Hack, MD, PhD, Managing Director of Bain Capital, to the JenaValve Board of Directors.ith Merck and Cancer Research UK providing a best-in-class pipeline of molecules that harness both direct and immune-mediated anti-cancer activities in solid cancers and cancer fibrosis.

(more…)

Read More

Sequana Medical announces first patient enrolled in RED DESERT – REpeated Dose alfapump® DSR study for Treatment of diuretic-resistant heart failure patients

The study aims to:

  • Evaluate the safety of alfapump DSR in patients with heart failure
  • Assess the feasibility of alfapump DSR to remove excess sodium and fluid from the body
  • Explore the potential impact of DSR therapy to restore response to diuretics

Ghent, BELGIUM – 7 January 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that the first patient has been enrolled in the first-in-human repeated dose study of alfapump DSR (Direct Sodium Removal) for the treatment of diuretic-resistant heart failure patients.

(more…)

Read More

La start-up Gamaya lève 12 millions de francs

Gamaya, active dans l’agriculture de précision, a levé 12 millions de francs dans le cadre d’un tour de financement de série B, dont 4,2 millions de francs sous forme d’obligations convertibles. Un tournant pour cette spin-off de l’EPFL.

(more…)

Read More
Menu